COVID-19
- Thread starter Wild Bill
- Start date
Cackalacky2.0
Specimen
- Messages
- 9,023
- Reaction score
- 8,018
For the record my wife got the booster and had zero problems
Rack Em
Community Bod
- Messages
- 7,089
- Reaction score
- 2,727
For the record, I did not get the booster and also had zero problems.
Rack Em
Community Bod
- Messages
- 7,089
- Reaction score
- 2,727
I'll just drop this turd in the punchbowl and then leave.
I worked in clinical research for a short time. The FDA and the pharma companies document every little possible thing that could be considered a side effect or adverse effect during drug trials. Those trials typically last for years and patients are followed for years after that. I'm simply not okay with putting something in my body when there are zero long term studies about the effects of the vaccine. I'm in my 30s and I plan to live for a long time. And part of that is not having to possibly deal with the adverse effects from the jab. I'm also not going to let Don Lemon, Joe Biden, Tony Fauci, my employer, or anyone else say "Shut up and let the nurse stick you with this needle! It's for your own good! You have a moral and patriotic duty to get tripled vaxxed! And if you don't, I'm going to shoot your dog!"
We do not know the long term effects. Covid is going to be a part of our lives. We have to learn to deal with it. Go get every Covid vaccination and wear your mask so Tony Fauci will come visit your house on Christmas, sneak down your chimney, and leave you a N-95 in your stocking for being a good little serf.
I'll take my health in my own hands. And I'll take my freedom with it too.
I worked in clinical research for a short time. The FDA and the pharma companies document every little possible thing that could be considered a side effect or adverse effect during drug trials. Those trials typically last for years and patients are followed for years after that. I'm simply not okay with putting something in my body when there are zero long term studies about the effects of the vaccine. I'm in my 30s and I plan to live for a long time. And part of that is not having to possibly deal with the adverse effects from the jab. I'm also not going to let Don Lemon, Joe Biden, Tony Fauci, my employer, or anyone else say "Shut up and let the nurse stick you with this needle! It's for your own good! You have a moral and patriotic duty to get tripled vaxxed! And if you don't, I'm going to shoot your dog!"
We do not know the long term effects. Covid is going to be a part of our lives. We have to learn to deal with it. Go get every Covid vaccination and wear your mask so Tony Fauci will come visit your house on Christmas, sneak down your chimney, and leave you a N-95 in your stocking for being a good little serf.
I'll take my health in my own hands. And I'll take my freedom with it too.
Last edited:
Polish Leppy 22
Well-known member
- Messages
- 6,594
- Reaction score
- 2,009
Keep backtracking. "Seems like I'm making the argument"??? So you took my text and turned it into your own interpretation, which is misdirection.
I didn't say the vaccine had no impact on rates. I pointed out that fully vaccinated people are testing positive for the virus, which goes against what was pushed down our throats for the past year. We were told the vaccine would end the virus, so questioning the effectiveness isn't a conspiracy theory or completely insane. Hopefully Omicron is the new common cold and we can all move on with life.
The big difference here is that I support everyone's decision to get it, but don't think anyone should be forced to get it.
Last edited:
- Messages
- 44,591
- Reaction score
- 20,044
Surprised they are even letting this news get out.
13 million put into lockdown in Chinese city
(CNN)On Tuesday, the central Chinese city of Xi'an recorded 52 new Covid-19 cases. By Wednesday, authorities had imposed strict lockdown measures on its estimated 13 million residents.
The sweeping restrictions, which prevent people from leaving their homes, come as the country braces for the Lunar New Year travel rush, followed by the 2022 Winter Olympics, due to begin in the capital Beijing on February 4.
Xi'an, an ancient city known internationally as the home of the 2,000-year-old Terracotta warriors sculptures, detected its first case connected to the latest outbreak at a quarantine hotel on December 9. The virus is believed to have then spread into the community via an infected hotel worker. Officials believe the cluster is linked to an inbound flight from Pakistan on December 4, where at least six passengers were found to have the Delta variant. So far, there have been no reported cases of the Omicron variant in Xi'an. Authorities moved swiftly, suspending schools and conducting mass testing for the entire city. Cases have continued to climb, however. Since December 9, the city has recorded a total of 206 cases. On Wednesday, authorities recorded 63 new locally transmitted cases, Xi'an's highest daily figure this month. Residents queue up for Covid tests at a testing site in Xi'an, China, on December 21.
By noon on Wednesday, more than 30,000 people who were believed to have come into contact with a confirmed case were placed in government quarantine, according to state-run newspaper China Daily. That same day, the city imposed a strict lockdown until further notice for all residents.
Xi'an is now designated a "controlled area," China's second-highest category of lockdown -- meaning residents are banned from leaving their homes except for urgent cases like medical emergencies. Each household is only allowed to send one designated person out of the house to buy groceries every two days. After the new restrictions were announced, families rushed to supermarkets to stock up on supplies before the lockdown went into effect at midnight, according to state-run tabloid the Global Times.
Schools, public facilities and transport systems are also closed except for essential service providers like hospitals and supermarkets, according to the local government's announcement.
Xi'an is one level away from the highest lockdown category of "sealed area," in which residents are completely banned from leaving their homes, and groceries are delivered to their door.
This is only the fourth time a major Chinese city has been placed under the "controlled area" lockdown. Though previous outbreaks have seen similar restrictions, they are typically only applied to specific areas where infections are most prevalent -- not an entire city.
The emergence of yet another outbreak has raised questions over the long-term viability of China's ambitious "zero-Covid" policy, which aims to eliminate the virus completely within the country's borders.
Despite administering more than 2.7 billion doses of its homegrown vaccines, authorities have struggled with a number of fast-spreading outbreaks. The outbreak in Xi'an follows a Delta-driven outbreak in the summer; a September outbreak in Fujian province; an October outbreak that spread to more than half the country; then several clusters in Inner Mongolia in November, which have spread to Zhejiang province in recent weeks.
In the past week alone, in addition to Xi'an, cases have also been recorded in Henan province, Zhejiang province, Guangdong province, Guangxi autonomous region, and the cities of Beijing and Tianjin.
13 million put into lockdown in Chinese city
(CNN)On Tuesday, the central Chinese city of Xi'an recorded 52 new Covid-19 cases. By Wednesday, authorities had imposed strict lockdown measures on its estimated 13 million residents.
The sweeping restrictions, which prevent people from leaving their homes, come as the country braces for the Lunar New Year travel rush, followed by the 2022 Winter Olympics, due to begin in the capital Beijing on February 4.
Xi'an, an ancient city known internationally as the home of the 2,000-year-old Terracotta warriors sculptures, detected its first case connected to the latest outbreak at a quarantine hotel on December 9. The virus is believed to have then spread into the community via an infected hotel worker. Officials believe the cluster is linked to an inbound flight from Pakistan on December 4, where at least six passengers were found to have the Delta variant. So far, there have been no reported cases of the Omicron variant in Xi'an. Authorities moved swiftly, suspending schools and conducting mass testing for the entire city. Cases have continued to climb, however. Since December 9, the city has recorded a total of 206 cases. On Wednesday, authorities recorded 63 new locally transmitted cases, Xi'an's highest daily figure this month. Residents queue up for Covid tests at a testing site in Xi'an, China, on December 21.
By noon on Wednesday, more than 30,000 people who were believed to have come into contact with a confirmed case were placed in government quarantine, according to state-run newspaper China Daily. That same day, the city imposed a strict lockdown until further notice for all residents.
Xi'an is now designated a "controlled area," China's second-highest category of lockdown -- meaning residents are banned from leaving their homes except for urgent cases like medical emergencies. Each household is only allowed to send one designated person out of the house to buy groceries every two days. After the new restrictions were announced, families rushed to supermarkets to stock up on supplies before the lockdown went into effect at midnight, according to state-run tabloid the Global Times.
Schools, public facilities and transport systems are also closed except for essential service providers like hospitals and supermarkets, according to the local government's announcement.
Xi'an is one level away from the highest lockdown category of "sealed area," in which residents are completely banned from leaving their homes, and groceries are delivered to their door.
This is only the fourth time a major Chinese city has been placed under the "controlled area" lockdown. Though previous outbreaks have seen similar restrictions, they are typically only applied to specific areas where infections are most prevalent -- not an entire city.
The emergence of yet another outbreak has raised questions over the long-term viability of China's ambitious "zero-Covid" policy, which aims to eliminate the virus completely within the country's borders.
Despite administering more than 2.7 billion doses of its homegrown vaccines, authorities have struggled with a number of fast-spreading outbreaks. The outbreak in Xi'an follows a Delta-driven outbreak in the summer; a September outbreak in Fujian province; an October outbreak that spread to more than half the country; then several clusters in Inner Mongolia in November, which have spread to Zhejiang province in recent weeks.
In the past week alone, in addition to Xi'an, cases have also been recorded in Henan province, Zhejiang province, Guangdong province, Guangxi autonomous region, and the cities of Beijing and Tianjin.
TorontoGold
Mr. Dumb Moron
- Messages
- 7,359
- Reaction score
- 5,709
Your misunderstanding is not someone else's fault, take ownership. The vaccine would effectively end the virus, if you see the hospitalization rates for people with the vaccine in the strains before delta it was incredible. Even with Delta vaccinated people were not filling up hospitals. If the hospitals aren't full then everyone wins and we can move on. But if anti-vaxxers are causing overrun at the hospital then cancer screenings and other preventive procedures can't be performed.
As Irishize has said we need to move on, I'm sick of restrictions because some idiot needs to do "their own research". My mother couldn't see a surgeon for QOL procedure for over 8 months, where's her choice?
calvegas04
Well-known member
- Messages
- 11,875
- Reaction score
- 8,448
My elderly mother and brother received it with no issue and no feeling sick like the first shots
Irishize
Well-known member
- Messages
- 4,531
- Reaction score
- 461
Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in studies from Oxford and Washington Universities
Ref: AstraZeneca
PUBLISHED: DECEMBER 23, 2021
AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retains neutralisation activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new authentic 'live' virus neutralisation data from both University College Oxford, UK and Washington University School of Medicine, St. Louis, US.
The findings were posted online on bioRxiv, a preprint server, here and here.
Evusheld's Inhibitory Concentration 50 (IC50), a measure of neutralising potency of an antibody, was 273 ng/ml and 147 ng/ml in the Oxford and Washington University studies, respectively.[SUP]1,2[/SUP] The levels are within the range of neutralising antibody titres found in individuals who have been previously infected with and recovered naturally from COVID-19.[SUP]3[/SUP]
The data were generated from laboratory testing using actual live virus isolated from individuals who contracted the Omicron variant of COVID-19, considered a 'gold standard' for antibody neutralisation studies.[SUP]4[/SUP]Evusheld is one of only two antibody therapies authorised for use that showed neutralising activity against Omicron and against all other variants of concern in these two studies.[SUP]1,2[/SUP]
These findings are in line with pseudovirus neutralising data from independent investigators at the US Food and Drug Administration (FDA) announced on 16 December 2021, and add to the growing body of preclinical evidence demonstrating that Evusheld retains activity against all tested SARS-CoV-2 variants of concern to date.[SUP]5[/SUP]
Stay on top of critical developments in top fields of interest. Learn more.
Sponsored by FirstWord Pharma
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: "Consistent data across three independent studies now provide confidence that Evusheld, a combination of two highly potent antibodies, retains neutralising activity against the Omicron variant at a level that will continue to provide benefit to patients. Evusheld is the only antibody therapy authorised for pre-exposure prophylaxis of COVID-19 in the US, and we're excited that Evusheld is now available to help protect vulnerable populations, such as the immunocompromised, who are unable to mount an adequate response to vaccination and who remain at high-risk for COVID-19."
By combining two particularly potent antibodies with different and complementary activities against the virus, Evusheld was designed to evade potential resistance with the emergence of new SARS-CoV-2 variants.
The Omicron variant was not in circulation during the Evusheld clinical trials. The Company is continuing to collect further data to better understand the implications of these data in clinical practice. Data from both studies will be submitted for publication in a peer-reviewed journal.
Evusheld received Emergency Use Authorisation (EUA) in the US in December 2021 for the pre-exposure prophylaxis (prevention) of COVID-19 in people with moderate to severe immune compromise due to a medical condition or immunosuppressive medications and who may not mount an adequate immune response to COVID-19 vaccination, as well as those individuals for whom COVID-19 vaccination is not recommended.
About 2% of the global population is considered at increased risk of an inadequate response to a COVID-19 vaccine.[SUP]6,7[/SUP] Recent emerging evidence indicate that protecting vulnerable populations from getting COVID-19 could help prevent viral evolution that is an important factor in the emergence of variants.[SUP]8[/SUP]
Notes
Evusheld
Evusheld, formerly known as AZD7442 is a combination of two LAABs - tixagevimab (AZD8895) and cilgavimab (AZD1061) - derived from B-cells donated by convalescent patients after SARS-CoV-2 virus. Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein[SUP]9[/SUP] and were optimised by AstraZeneca with half-life extension and reduced Fc receptor and complement C1q binding. The half-life extension more than triples the durability of its action compared to conventional antibodies and could afford up to 12 months of protection from COVID-19 following a single administration;[SUP]10-12 [/SUP]data from the Phase III PROVENT trial show protection lasting at least six months.[SUP]13[/SUP] The reduced Fc receptor binding aims to minimise the risk of antibody-dependent enhancement of disease - a phenomenon in which virus-specific antibodies promote, rather than inhibit, infection and/or disease.[SUP]14 [/SUP]Evusheld is delivered as an IM dose of 150mg tixagevimab and 150mg cilgavimab administered in two separate, consecutive injections.
In December 2021, the FDA issued an EUA for the use of Evusheld for the pre-exposure prophylaxis (prevention) of COVID-19. It is the only antibody authorised in the US to prevent COVID-19 symptoms before virus exposure. Evusheld is also authorised for emergency use for prevention of COVID-19 in several other countries.
In August 2021, AstraZeneca announced that Evusheld demonstrated a statistically significant reduction in the risk of developing symptomatic COVID-19 in the PROVENT trial; efficacy was 83% compared to placebo in a six-month analysis announced on 18 November 2021. In October 2021, AstraZeneca announced positive high-level results from the Evusheld TACKLE Phase III outpatient treatment trial. Evusheld is also being studied as a potential treatment for hospitalised COVID-19 patients as part of the National Institute of Health's ACTIV-3 trial and in an additional collaborator hospitalisation treatment trial.
Evusheld is being developed with support from the US government, including federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, under Contract No. W911QY-21-9-0001.
Under the terms of the licensing agreement with Vanderbilt, AstraZeneca will pay single-digit royalties on future net sales.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
References
1. Dejnirattisai W, et al. Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. bioRxiv. 2021; doi: 10.1101/2021.12.03.471045.
2. VanBlargan LA, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies. bioRxiv. 2021; doi: 10.1101/2021.12.15.472828.
3. Neerukonda SN et al. Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. PLoS ONE. 2021.16(3): e0248348. Available at: https://journals.plos.org/plosone/ar...l.pone.0248348 [Last accessed: December 2021].
4. Shi AC, et al. SARS-CoV-2 serology testing: Progress and challenges. J Immunol Methods. 2021 Jul; 494: 113060. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071778/ [Last accessed: December 2021]
5. ACTIV. National Center for Advancing Translational Sciences Open Data Portal. SARS-CoV-2 Variants & Therapeutics, All Variants Reported in vitro Therapeutic Activity. Available at: https://opendata.ncats.nih.gov/variant/activity. [Last accessed: December 2021].
6. Oliver, S MD. Data and clinical considerations for additional doses in immunocompromised people. ACIP Meeting July 22, 2021. Available at: https://www.cdc.gov/vaccines/acip/me...Oliver-508.pdf. [Last accessed: December 2021].
7. AstraZeneca data on file.
8. Corey L, et al. SARS-CoV-2 Variants in Patients with Immunosuppression. N Engl J Med 2021; 385:562-566. DOI: 10.1056/NEJMsb2104756.
9. Dong J, et al. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. bioRxiv. 2021; doi: 10.1101/2021.01.27.428529.
10. Robbie GJ, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013; 57 (12): 6147-53.
11. Griffin MP, et al. Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob Agents Chemother. 2017; 61(3): e01714-16.
12. Domachowske JB, et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr Infect Dis J. 2018; 37(9): 886-892.
13. AstraZeneca news release. New analyses of two AZD7442 COVID-19 trials in high-risk populations confirm robust efficacy and long-term prevention. Available at: https://www.astrazeneca.com/media-ce...revention.html. [Last accessed: December 2021].
14. van Erp EA, et al. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol. 2019; 10: 548.
Ref: AstraZeneca
PUBLISHED: DECEMBER 23, 2021
AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retains neutralisation activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new authentic 'live' virus neutralisation data from both University College Oxford, UK and Washington University School of Medicine, St. Louis, US.
The findings were posted online on bioRxiv, a preprint server, here and here.
Evusheld's Inhibitory Concentration 50 (IC50), a measure of neutralising potency of an antibody, was 273 ng/ml and 147 ng/ml in the Oxford and Washington University studies, respectively.[SUP]1,2[/SUP] The levels are within the range of neutralising antibody titres found in individuals who have been previously infected with and recovered naturally from COVID-19.[SUP]3[/SUP]
The data were generated from laboratory testing using actual live virus isolated from individuals who contracted the Omicron variant of COVID-19, considered a 'gold standard' for antibody neutralisation studies.[SUP]4[/SUP]Evusheld is one of only two antibody therapies authorised for use that showed neutralising activity against Omicron and against all other variants of concern in these two studies.[SUP]1,2[/SUP]
These findings are in line with pseudovirus neutralising data from independent investigators at the US Food and Drug Administration (FDA) announced on 16 December 2021, and add to the growing body of preclinical evidence demonstrating that Evusheld retains activity against all tested SARS-CoV-2 variants of concern to date.[SUP]5[/SUP]
Stay on top of critical developments in top fields of interest. Learn more.
Sponsored by FirstWord Pharma
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: "Consistent data across three independent studies now provide confidence that Evusheld, a combination of two highly potent antibodies, retains neutralising activity against the Omicron variant at a level that will continue to provide benefit to patients. Evusheld is the only antibody therapy authorised for pre-exposure prophylaxis of COVID-19 in the US, and we're excited that Evusheld is now available to help protect vulnerable populations, such as the immunocompromised, who are unable to mount an adequate response to vaccination and who remain at high-risk for COVID-19."
By combining two particularly potent antibodies with different and complementary activities against the virus, Evusheld was designed to evade potential resistance with the emergence of new SARS-CoV-2 variants.
The Omicron variant was not in circulation during the Evusheld clinical trials. The Company is continuing to collect further data to better understand the implications of these data in clinical practice. Data from both studies will be submitted for publication in a peer-reviewed journal.
Evusheld received Emergency Use Authorisation (EUA) in the US in December 2021 for the pre-exposure prophylaxis (prevention) of COVID-19 in people with moderate to severe immune compromise due to a medical condition or immunosuppressive medications and who may not mount an adequate immune response to COVID-19 vaccination, as well as those individuals for whom COVID-19 vaccination is not recommended.
About 2% of the global population is considered at increased risk of an inadequate response to a COVID-19 vaccine.[SUP]6,7[/SUP] Recent emerging evidence indicate that protecting vulnerable populations from getting COVID-19 could help prevent viral evolution that is an important factor in the emergence of variants.[SUP]8[/SUP]
Notes
Evusheld
Evusheld, formerly known as AZD7442 is a combination of two LAABs - tixagevimab (AZD8895) and cilgavimab (AZD1061) - derived from B-cells donated by convalescent patients after SARS-CoV-2 virus. Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein[SUP]9[/SUP] and were optimised by AstraZeneca with half-life extension and reduced Fc receptor and complement C1q binding. The half-life extension more than triples the durability of its action compared to conventional antibodies and could afford up to 12 months of protection from COVID-19 following a single administration;[SUP]10-12 [/SUP]data from the Phase III PROVENT trial show protection lasting at least six months.[SUP]13[/SUP] The reduced Fc receptor binding aims to minimise the risk of antibody-dependent enhancement of disease - a phenomenon in which virus-specific antibodies promote, rather than inhibit, infection and/or disease.[SUP]14 [/SUP]Evusheld is delivered as an IM dose of 150mg tixagevimab and 150mg cilgavimab administered in two separate, consecutive injections.
In December 2021, the FDA issued an EUA for the use of Evusheld for the pre-exposure prophylaxis (prevention) of COVID-19. It is the only antibody authorised in the US to prevent COVID-19 symptoms before virus exposure. Evusheld is also authorised for emergency use for prevention of COVID-19 in several other countries.
In August 2021, AstraZeneca announced that Evusheld demonstrated a statistically significant reduction in the risk of developing symptomatic COVID-19 in the PROVENT trial; efficacy was 83% compared to placebo in a six-month analysis announced on 18 November 2021. In October 2021, AstraZeneca announced positive high-level results from the Evusheld TACKLE Phase III outpatient treatment trial. Evusheld is also being studied as a potential treatment for hospitalised COVID-19 patients as part of the National Institute of Health's ACTIV-3 trial and in an additional collaborator hospitalisation treatment trial.
Evusheld is being developed with support from the US government, including federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, under Contract No. W911QY-21-9-0001.
Under the terms of the licensing agreement with Vanderbilt, AstraZeneca will pay single-digit royalties on future net sales.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
References
1. Dejnirattisai W, et al. Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. bioRxiv. 2021; doi: 10.1101/2021.12.03.471045.
2. VanBlargan LA, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies. bioRxiv. 2021; doi: 10.1101/2021.12.15.472828.
3. Neerukonda SN et al. Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. PLoS ONE. 2021.16(3): e0248348. Available at: https://journals.plos.org/plosone/ar...l.pone.0248348 [Last accessed: December 2021].
4. Shi AC, et al. SARS-CoV-2 serology testing: Progress and challenges. J Immunol Methods. 2021 Jul; 494: 113060. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071778/ [Last accessed: December 2021]
5. ACTIV. National Center for Advancing Translational Sciences Open Data Portal. SARS-CoV-2 Variants & Therapeutics, All Variants Reported in vitro Therapeutic Activity. Available at: https://opendata.ncats.nih.gov/variant/activity. [Last accessed: December 2021].
6. Oliver, S MD. Data and clinical considerations for additional doses in immunocompromised people. ACIP Meeting July 22, 2021. Available at: https://www.cdc.gov/vaccines/acip/me...Oliver-508.pdf. [Last accessed: December 2021].
7. AstraZeneca data on file.
8. Corey L, et al. SARS-CoV-2 Variants in Patients with Immunosuppression. N Engl J Med 2021; 385:562-566. DOI: 10.1056/NEJMsb2104756.
9. Dong J, et al. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. bioRxiv. 2021; doi: 10.1101/2021.01.27.428529.
10. Robbie GJ, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013; 57 (12): 6147-53.
11. Griffin MP, et al. Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob Agents Chemother. 2017; 61(3): e01714-16.
12. Domachowske JB, et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr Infect Dis J. 2018; 37(9): 886-892.
13. AstraZeneca news release. New analyses of two AZD7442 COVID-19 trials in high-risk populations confirm robust efficacy and long-term prevention. Available at: https://www.astrazeneca.com/media-ce...revention.html. [Last accessed: December 2021].
14. van Erp EA, et al. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol. 2019; 10: 548.
Polish Leppy 22
Well-known member
- Messages
- 6,594
- Reaction score
- 2,009
You challenged me on my position. I posted cases and statistics to support my position. You didn't foresee that, couldn't disprove what I said, and are now taking this in any direction you can to save face. It's embarrassing. Move on.
If the vaccine would effectively end the virus, vaccinated people wouldn't be testing positive. Again, my greatest hope is that this thing has mutated into omicron, the new common cold, and we can all move on with life.
TorontoGold
Mr. Dumb Moron
- Messages
- 7,359
- Reaction score
- 5,709
You mean the stats that you posted in response to Phork and 23, and they challenged them? That you haven't responded to? Or your handful of anecdotes you posted in response to me?
Boy, I'm glad you pulled the fork out of the outlet to type this. This is incredibly telling. Despite numerous people from the start and until now that this was never the purpose of the vaccine, you're still parroting this take.
Polish Leppy 22
Well-known member
- Messages
- 6,594
- Reaction score
- 2,009
You're either more lost than I thought or you just can't comprehend. First you take my post and twist it into an entirely different argument you formulated on your own, which I didn't say.
Then you say I didn't respond to you and others, when in fact I did.
Now you're saying the unvaccinated people are overwhelming hospitals and spreading the virus, but the purpose of the vaccine isn't to eliminate the virus. Just to remind you how far off the path you've gone, my original argument was that the omicron variant is far less deadly and symptoms are nothing more than the common cold.
GATTACA!
It's about to get gross
- Messages
- 15,105
- Reaction score
- 12,943
Stupid useless flu vaccine hasn't eliminated influenza either.
ab2cmiller
Troublemaker in training
- Messages
- 11,453
- Reaction score
- 8,532
That's just because we haven't mandated it .............. yet.
Valpodoc85
Well-known member
- Messages
- 1,719
- Reaction score
- 466
I posted this some months back, there is a famous virologist named Robert Gallo. He is one of the guys credited with the discovery of HIV. He felt at the beginning of this pandemic it would be an uphill hill slog as the covid spike protein is glycosylated (has sugar stuck to it). This somehow changes our immune response by limiting its duration. He noted this is the problem with the HIV vaccine. He felt the response would be on the 3-6 month duration. Amazingly spot on. This does not mean the vaccine is useless, only it’s utility is limited. Also with the HIV vaccine they noted a reduction in response with multiple boosters.
Currently, one of the big uses of the vaccine is limiting hospital exposure. And let me tell you there are a lot of really tired, defeated, frustrated medical personnel. The nurses have taken the brunt of it and god bless everyone that goes back into the breach everyday. If you know a nurse or doctor get vaccinated or boosted for them.
Currently, one of the big uses of the vaccine is limiting hospital exposure. And let me tell you there are a lot of really tired, defeated, frustrated medical personnel. The nurses have taken the brunt of it and god bless everyone that goes back into the breach everyday. If you know a nurse or doctor get vaccinated or boosted for them.
Polish Leppy 22
Well-known member
- Messages
- 6,594
- Reaction score
- 2,009
No argument there, but the narrative never was "if you don't get your flu shot you're selfish and responsible for the flu killing other people."
Cackalacky2.0
Specimen
- Messages
- 9,023
- Reaction score
- 8,018
My sister is one of them.
Irishize
Well-known member
- Messages
- 4,531
- Reaction score
- 461
So is my wife & mother-in-law….both RNs
GATTACA!
It's about to get gross
- Messages
- 15,105
- Reaction score
- 12,943
If the flu killed 24x as many people (815k vs 34k) and had infected 17x as many (52m vs 3m) in a single year I'm sure that would be the narrative.
ulukinatme
Carr for QB 2025!
- Messages
- 31,518
- Reaction score
- 17,385
The problem is the jab was never meant to provide immunity unlike true vaccines, it was only meant to reduce the virus' effects to keep people out of the ER. For that reason there was never going to be a way to fully stop this thing. As expected a lot of publications are now suggesting this pandemic is moving toward endemic which means it'll probably always be around like the flu, but it'll be more seasonal and the effects are expected to be more manageable as we're hopefully seeing with this current Omicron variant.
chicago51
Well-known member
- Messages
- 3,658
- Reaction score
- 387
I’m a medical professional, and have talked to people who know a lot about this. The vaccine was over promised but it works on severe disease level. Covid like flu is a mucosal virus meaning it can replicate in nose / upper airway. You got some antibodies in your nasal mucus but you don’t got the same level of t-cells, b-cells, and really everything your body uses to fight pathogens in your nasopharynx. Besides antibodies you get a t-cell / b-cell response from the vaccine as well as nature infection. The protection you get from t-cells, memory b-cells (which last much much longer than antibodies by the way; talking years here in healthy people) is going to much more significant in your blood than in your nose.
In vaccinated people especially if time has lapsed since the vaccine this virus can breakthrough the antibody wall with enough exposure and replicate in the your nose / upper airway. But it’s through the immune cells in your blood where you are going to get protection for your critical organs and thus protection from severe disease.
The issue is for the elderly and immuno compromised is your b-cells / t-cells aren’t as numerous and don’t work as optimal anymore, hence it’s this population where breakthrough deaths generally occur the vast majority of the time.
In vaccinated people especially if time has lapsed since the vaccine this virus can breakthrough the antibody wall with enough exposure and replicate in the your nose / upper airway. But it’s through the immune cells in your blood where you are going to get protection for your critical organs and thus protection from severe disease.
The issue is for the elderly and immuno compromised is your b-cells / t-cells aren’t as numerous and don’t work as optimal anymore, hence it’s this population where breakthrough deaths generally occur the vast majority of the time.
ulukinatme
Carr for QB 2025!
- Messages
- 31,518
- Reaction score
- 17,385
For some reason my browser keeps cutting off part of the article, but some interesting points and mentions of immune system fatigue.
[TWEET]https://twitter.com/AAPSonline/status/1474097894005215236[/TWEET]
[TWEET]https://twitter.com/AAPSonline/status/1474097894005215236[/TWEET]
NorthDakota
Grandson of Loomis
- Messages
- 15,701
- Reaction score
- 6,002
We haven't got tested yet but it seems COVID may have entered the household lol. I had some chills yesterday, my neice has a cold. My sister can't taste or smell. And the other sister is not feeling good apparently.
Irishize
Well-known member
- Messages
- 4,531
- Reaction score
- 461
Get well soon bro
NorthDakota
Grandson of Loomis
- Messages
- 15,701
- Reaction score
- 6,002
I think I'm better. Don't feel chilly today.
ACamp1900
Counting my ‘bet against ND’ winnings
- Messages
- 48,947
- Reaction score
- 11,225
Considering you almost certainly live in a van down by the river I’d say you’re probably running a fever
NorthDakota
Grandson of Loomis
- Messages
- 15,701
- Reaction score
- 6,002
I could snort AIDS and it wouldn't phase me
Wild Bill
Well-known member
- Messages
- 5,518
- Reaction score
- 3,263
Not if she showers afterwards.
Blazers46
Adjectives: wise/brilliant/handsome.
- Messages
- 8,107
- Reaction score
- 5,459
If you wore a mask all is well….